CytRx Corporation (CYTR)
(Delayed Data from NSDQ)
$0.51 USD
-0.02 (-3.66%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.51 USD
-0.02 (-3.66%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Zacks.com featured highlights include: Ralph Lauren, Estee Lauder, GMS, CytRx and T2 Biosystems
by Zacks Equity Research
Zacks.com featured highlights include: Ralph Lauren, Estee Lauder, GMS, CytRx and T2 Biosystems
Bet on Rising P/E Investing With These 5 Top-Ranked Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
5 Biotech Stocks Under $10 Worthy of Investors' Attention
by Indrajit Bandyopadhyay
Small biotech stocks are good bets with lower market cap as well as share price.
CytRx Gets Clarity from FDA for Aldoxorubicin NDA, Shares Up
by Zacks Equity Research
CytRx Corporation (CYTR) announced that the it has reached an agreement with the regarding the path to filing for its new drug application (NDA) for its lead candidate aldoxorubicin being developed for the treatment of soft tissue sarcomas (STS).
Is the Options Market Predicting a Spike in CytRx Corp (CYTR) Stock?
by Zacks Equity Research
Options traders are pricing in a big move for CytRx Corp (CYTR) shares as it has huge implied volatility
New Strong Buy Stocks for July 29th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
New Strong Buy Stocks for July 25th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
New Strong Buy Stocks for July 14th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
New Strong Buy Stocks for July 5th
by Zacks Equity Research
Here are 4 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday